[A new derivative of yperite for oral and intramuscular administration: bis-(2-chloroethyl) beta-naphthylamine in cancer].
D015081:2-Naphthylamine; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008466:Mechlorethamine; D009151:Mustard Gas; D009281:Naphthalenes / Q000031:analogs & derivatives; D009369:Neoplasms; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*
D009281:Naphthalenes; D009588:Nitrogen Mustard Compounds; C031721:naphthalene; D008466:Mechlorethamine; D015081:2-Naphthylamine; D009151:Mustard Gas
HODGKIN'S DISEASE/therapy; LEUKEMIA/therapy; NAPHTHALENE/derivatives; NITROGEN MUSTARDS/therapeutic use
Contribution à l'étude d'un nouveau dérivé de l'ypérite à administration orale et intramusculaire: le bis-(2-chloroethyl) beta-naphtylamine dans les maladies concéreuses.